Deborah Locke
Payments from drug & device makers
Across 79 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$268
- Viiv Healthcare Company$223
- Gilead$165
- Merck$143
- Johnson & Johnson$101
- Novo Nordisk$93
- plus $448 from 13 others
What the payments were for
- Food & beverage$1,441100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $268 |
| Viiv Healthcare Company | 10 | $223 |
| Gilead | 12 | $165 |
| Merck | 8 | $143 |
| Johnson & Johnson(2 entities) | 5 | $101 |
| Novo Nordisk | 5 | $93 |
| AstraZeneca | 6 | $89 |
| Amgen | 3 | $55 |
| Boehringer Ingelheim | 3 | $54 |
| Abbott | 2 | $46 |
| Pfizer | 2 | $34 |
| Eisai Inc. | 1 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Novartis | 1 | $25 |
| Medtronic | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Teleflex LLC | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Lucid Diagnostics Inc. | 1 | $14 |
How this compares
$1,441 in reported general payments places this provider in the 65th percentile of 748 medical providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 15 | $18,144 |
| FarxigaDapagliflozin Propanediol | 13 | $11,608 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,944 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,327 |
| Ezetimibe | 12 | $1,498 |
| Rosuvastatin Calcium | 35 | $1,439 |
| SynthroidLevothyroxine Sodium | 11 | $1,159 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $753 |
| Atorvastatin Calcium | 62 | $487 |
| Fluticasone Propionate | 25 | $448 |
| Levothyroxine Sodium | 37 | $319 |
| Gabapentin | 19 | $293 |
| Losartan Potassium | 25 | $253 |
| Metoprolol Succinate | 19 | $248 |
| Testosterone Cypionate | 13 | $248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $93 | $18,14415 claims |
| AstraZenecaFarxiga | $89 | $11,60813 claims |
| AbbVieSynthroid | $268 | $1,15911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 748 medical providers in Arizona.
Other medical in Tempe
- Robert CasquejoScottsdale$474K
- Andrew HicksPeoria$460K
- Darren WestScottsdale$206K
- Linda MoorsTucson$122K
- Jamie WystrachScottsdale$79K
- Scott YoungPhoenix$69K
- Scott LightfootPhoenix$61K
- Jennifer KiserPhoenix$53K
- Lakeisha ColterPhoenix$48K
- Amy IngersollPhoenix$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.